Immunogenicity after COVID-19 vaccines in Adapted Schedules

Project Details

Description

Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vaccine (COVID-19 Vaccine Moderna®; Moderna) and COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria®, AstraZeneca)
Trial design: A prospective, post marketing, randomized, partially single blind, multicenter, interventional study
AcronymIMCOVAS
StatusActive
Effective start/end date21/05/2130/06/22

Funding

  • KCE: €452,766.02